Compare Advance Auto Parts, Inc. (AAP) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Advance Auto Parts, Inc. vs Regeneron Pharmaceuticals Inc — how do they compare? Advance Auto Parts, Inc. trades at $52.93 (market cap $3.36B), while Regeneron Pharmaceuticals Inc trades at $796.38 (market cap $83.19B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 24.8× Advance Auto Parts, Inc.'s market cap, and Advance Auto Parts, Inc. pays the higher dividend (1.79%). Which is the better fit depends on your goals.
| AAP | REGN | |
|---|---|---|
Market Cap | $3.36B | $83.19B |
Sector | Consumer Cyclical | Health |
52-Week High | $64.17 | $812.27 |
52-Week Low | $38.75 | $555.51 |
Enterprise Value | $5.63B | $77.90B |
Dividend Yield | 1.79% | 0.47% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Advance Auto Parts (AAP) trades at $57.80, down 0.21% on the day, with a bullish technical signal and key support at $57. The company shows mixed fundamentals: a low P/S of 0.41 and strong recent earnings beats, but thin net margins of 0.51% and negative operating cash flow in 2025. News highlights restructuring efforts and AI-driven delivery initiatives as potential growth catalysts.
The outlook is cautiously optimistic; analyst consensus targets $61.30 with a buy rating, but high debt and competitive pressures pose risks. Earnings momentum and valuation appeal offer upside, yet execution on turnaround plans is critical for sustained recovery.
Regeneron Pharmaceuticals (REGN) trades at $784.36, up 1.59% today, with a bullish technical signal from moving averages but overbought RSI readings. The company shows strong profitability with a net income margin of 27.86% and has beaten EPS estimates in recent quarters. However, multiple class-action lawsuits filed in August 2026 allege inadequate clinical-trial risk disclosures, creating investor uncertainty amid solid financial performance.
Outlook remains supported by earnings momentum and analyst buy ratings, but legal risks and high valuation multiples pose near-term headwinds. Investment opportunity hinges on legal resolution and sustained drug pipeline success, while risks include trial setbacks and regulatory scrutiny.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Advance Auto Parts, Inc.
Advance Auto Parts is one of the industry's largest retailers of aftermarket automotive parts, tools, and accessories to do-it-yourself customers in North America. Advance operated 4,972 stores as of the end of 2021, in addition to servicing 1,317 independently owned Carquest stores. The company's Worldpac unit is a premier distributor of imported original-equipment parts. Advance derived 58% of its 2021 sales from commercial clients, up from 30%-40% before the General Parts deal.
Read more on AAP →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
